december, 2018

17decAll DayACHN Phase 2 ACH-4471

Event Details

ACH-4471 for C3 glomerulopathy (C3G) and Paroxysmal nocturnal hemoglobinuria (PNH). Phase 2 interim data due December 17, 2018.

ACH-4471, Complement Factor D Inhibitor for PNH and C3G

Achillion’s first generation oral factor D inhibitor, ACH-4471 is being evaluated for safety and efficacy with Phase 2 clinical programs in both paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G).

The PNH program consists of two trials: A Phase 2 clinical trial in untreated PNH patients where ACH-4471 is being assessed as a monotherapy; the second trial is Phase 2 clinical trial evaluating ACH-4471 in patients who are inadequately controlled or sub-optimally responding to eculizumab, which is a therapy for patients with PNH.

The C3G program consists of three currently recruiting Phase 2 clinical trials: a 14-day biomarker study, a six-month blinded, placebo-controlled study, and a 12-month open label study.

More information is available at http://www.achillion.com/patients-and-clinicians/

ACH-5228 and ACH-5548, Complement Factor D Inhibitors

ACH-5228 and ACH-5548 are next-generation oral factor D inhibitors currently in Phase 1 clinical trials. In preclinical studies, these compounds demonstrated enhanced potency as well as improved pharmacokinetic properties that may allow for a reduced dosing frequency.

Achillion plans to provide interim data on all open-label ACH-4471 clinical trials as well as Phase 1 safety and pharmacokinetics interim data from the single ascending dose trials of its next-generation factor D compounds, ACH-5228 and ACH-5548, on December 17, 2018.



Achillion Pharmaceuticals News

Time

All Day (Monday)

Go top

This website uses cookies to guarantee the best experience for the user. If you continue browsing, we consider that you agree to their use. For more information click here.

X